226
Participants
Start Date
July 20, 2010
Primary Completion Date
November 15, 2016
Study Completion Date
December 9, 2016
CC-223
Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
NYU Cancer Institute - Bellevue Hospital, New York
Institut Claudius Regaud, Toulouse
Moffitt Cancer Center, Tampa
Hospital Universitario de Salamanca, Salamanca
Sarah Cannon Research Institute Drug Development Unit, Nashville
Hospital Universitario Virgen Del Rocio, Seville
Mayo Clinic Cancer Clinical Studies Unit, Rochester
Billings Clinic, Billings
Mary Crowley Medical Research Center, Dallas
Cedars-Sinai Medical Center, Los Angeles
UCLA Neuro-Oncology Program, Los Angeles
University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco
Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif
Hackensack University Medical Center, Hackensack
Sarah Cannon Research Institute UK, London
UCL Cancer Institute, London
Lead Sponsor
Celgene
INDUSTRY